Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

7013Background: MRD negativity is a key prognostic indicator of patient (pt) outcome in ALL and is predictive of improved survival and disease-free status. In the INO-VATE ALL trial (Kantarjian, NE...